TCLlnc1 could be exploited as a possible biomarker for PTCL prognosis as it aws associated with high-risk clinical characteristics and poor prognosis.566 Overexpression of TCL1nc1 enhanced PTCL cell proliferation and migration in vitro and in vivo.566 TCLlnc1 interacted with the transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and the Y-box binding protein-1 (YBX1) as a modular scaffold, thereby upregulating the transcription of the TGFB2 and TGFBR1 genes and activating the tumor growth factor-β signaling pathway, leading to lymphoma progression.566. This evidence concerns the gene HNRNPD and lymphoma.